Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 7, 2011

View Archived Issues

Findings reported from REFLEX and MOSAIC trials of IFN-beta1a

Final results available of first OvaSave trial in Crohn's disease

Two PentaStaph vaccine components are immunogenic in phase I/II testing

Study compares Merck & Co. 15-valent pneumococcal conjugate vaccine to Prevnar

Roche presents highlights of third quarter 2011

Shigamabs well tolerated to date in phase II trial

Shire reviews developments of third quarter 2011

XTL Biopharmaceuticals set to acquire technology being developed for cartilage-related diseases

OXiGENE discloses final data from FALCON study

Randomization begins in phase IIb study of Jennerex's JX-594 in advanced liver cancer

Pfizer returns worldwide rights to TNF-alpha-targeted Nanobodies

Novel radioprotective agents divulged by Peter MacCallum Cancer Centre

Merck & Co. discloses new fatty-acid amide hydrolase 1 inhibitors

CancerTYPE ID test can improve outcome of patients with cancer

Verseon presents novel thrombin inhibitors

Rexahn Pharmaceuticals presents phase IIb data on Serdaxin

New GPR119 receptor agonists claimed

RegeneRx announces phase II RGN-259 data

FDA finds no link between ADHD medications and adverse cardiovascular events

Arena Pharmaceuticals patents new molecules for type 2 diabetes and obesity

Ongoing phase IIa trial in hepatitis C adds four treatment arms

Pfizer files application in Japan seeking approval for new indication of Sutent

FDA approves Bayer's Xarelto for new indication

FDA provides update on safety review of TNF blockers

SYGNIS' AXIS 2 trial advances

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...